"Meningiomas are tumors that originate from the arachnoidal cap cells of the leptomeninges. With an incidence rate of 8.36 per 100, 000 population, they are the most common primary central nervous system (CNS) tumors, accounting for a third of all cases. The World Health Organization (WHO) classification has traditionally categorized meningiomas into 15 different histopathological subtypes and three clinical grades. Tumors are classified as WHO grades 1, 2 or 3 based largely on histopathological features such as mitotic activity, presence of brain invasion, and other atypical features. However, there is increasing recognition of the limitations of histopathology including but not limited to: confounding factors such as sampling bias in a heterogeneous tumor, and technical factors related to the experience of the grading pathologist. Even with careful histologic grading, there remains significant variability in recurrence rates within each tumor grade. As more studies have uncovered the molecular features of meningiomas, novel biological alterations have helped refine classification schemes that more accurately reflect patient outcomes. This book reviews the current state of knowledge on the genomic and epigenomic landscape of meningiomas in order to identify the roles of genomic aberrations on diagnosis, prognosis, and treatment of meningiomas in addition to mainstays of surgical management, radiation therapy, and potential novel chemotherapies. Written by a team of world-renowned experts in neurosurgery, neuropathology, radiology, and radiation-oncology, this book is the definitive resource on meningioma management and investigation for both clinicians and scientists alike."

Provides a comprehensive review of the current clinical and molecular landscape of meningioma research Written by world-renowned experts in neurosurgery, neuropathology, radiology, radiation-oncology A definitive resource on meningioma management and investigation for clinicians and scientists

Autorentext
Gelareh Zadeh is a Professor at the Department of Surgery University of Toronto. She is a Neurosurgeon-Scientist at Toronto Western Hospital, University Health Network. She was most recently appointed as the Wilkins Family Chair in Brain Tumor Research. Her research laboratory is focused on studying the molecular mechanisms of glioma angiogenesis and molecular regulators of tumour metabolism.

Rolan Goldbrunner is Professor in the Department of General Neurosurgery and Head of the Center for Neurosurgery at the University of Cologne in Germany. He is the Past President of the German Society for Neurosurgery. His special focus is on brain tumours.

Boris Krischek is a Neurosurgeon at Les Hôpitaux Robert Schuman in Luxembourg and Professor in the Department of General Neurosurgery at the University of Cologne in Germany. 

Farshad Nassiri is a Neurosurgery Resident at University of Toronto and a member of Zadeh Lab. 

Inhalt
Chapter 1. Introduction and History of Meningiomas.- Chapter 2. Clinical Presentation and Prognosis.- Chapter 3. Imaging Characteristics of Meningiomas.- Chapter 4. Histopathology of Meningiomas.- Chapter 5. Skull Base Meningiomas.- Chapter 6. Spinal Meningiomas.- Chapter 7. Surgical Therapies.- Chapter 8. Radiation Therapies.- Chapter 9. Illustrative Cases.- Chapter 10. Advances in CNS Tumor Classification.- Chapter 11. Genomic Landscape.- Chapter 12. Radiation-Induced Meningiomas.- Chapter 13. Meningioma Predisposing Syndromes.- Chapter 14. Epigentic Landscape.- Chapter 15. Immune Profile.- Chapter 16. PDX Models/Mouse Models/Cell Lines.- Chapter 17. Novel Medical Therapies .- Chapter 18. Quality of Life in Menigioma Patients .- Chapter 19. Illustrative Cases: Revisited with Adjuvant Molecular Data .- Chapter 20. Future Directions in Management.